Search Within

Stuart Lichtman

  1. "Dmitriy Zamarin"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (2)
Groups
  1. Department of Medicine (6)
  2. GDMT, Medicine (6)
  3. Gynecologic Medicine Service (6)
  4. Gynecology Disease Management Team (6)
  5. Hematologic Malignancies, Division of (6)
  6. Solid Tumor Oncology Division (6)

More Groups

People
  1. Carol Aghajanian (6)
  2. Dmitriy Zamarin (6)
  3. Roisin O'Cearbhaill (6)
  4. Alexia Iasonos (5)
  5. Jason Konner (5)
  6. Qin Zhou (5)

More People

Years
  1. 2023 (1)
  2. 2022 (3)
  3. 2019 (2)
Publications
  1. Journal of Clinical Oncology (3)
  2. Gynecologic Oncology (2)
  3. Clinical Cancer Research (1)
Publishers
  1. American Society of Clinical Oncology (3)
  2. Elsevier Inc. (2)
  3. American Association for Cancer Research (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
    Journal Article

    Rubinstein, M. M.; Doria, E. R.; Konner, J.; Lichtman, S.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Troso-Sandoval, T.; Friedman, C.; O'Cearbhaill, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)
    Meeting Abstract

    Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Dysfunctional CD8+T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC)
    Meeting Abstract

    Friedman, C. F.; Zhou, Q.; Iasonos, A.; Holland, A.; Ramirez, L.; Grisham, R. N.; Guo, R.; Lichtman, S. M.; Kyi, C.; Makker, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer
    Journal Article

    Manning-Geist, B. L.; Gordhandas, S. B.; Giri, D. D.; Iasonos, A.; Zhou, Q.; Girshman, J.; O'Cearbhaill, R. E.; Zamarin, D.; Lichtman, S. M.; Sabbatini, P. J.; more...
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • A phase 2 study of TPIV200/ huFR-1 (a multi-epitope folate receptor alpha vaccine) in combination with durvalumab in patients with platinum resistant ovarian cancer
    Meeting Abstract

    Zamarin, D.; Yeku, O.; O'Cearbhaill, R. E.; Cadoo, K. A.; Gallagher, J.; Kravetz, S.; McDonnell, A.; Troso-Sandoval, T.; Sabbatini, P.; Lichtman, S.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma
    Meeting Abstract

    Rubinstein, M. M.; Caird, I.; Zhou, Q.; Iasonos, A.; Friedman, C. F.; Cadoo, K. A.; Konner, J. A.; O'Cearbhaill, R. E.; Tew, W. P.; Zamarin, D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save